Cell Mediated and Humoral Immune responses to Mumps Virus: Recent Developments by Mahon, Bernard P. & Flynn, Marion A.
M. Flynn & B.P. Mahon               Chapter 6: Immune Response to Mumps Viruses 
Recent Research Developments in Virology, 5 (2003):97-115  ISBN:81-7895-094-4  
6 
Cell Mediated And Humoral Immune 
Responses To Mumps Virus: 
Recent Developments 
Marion Flynn and Bernard P. Mahon 
 
Mucosal Immunology Laboratory, Institute of Immunology, NUI 
Maynooth, Co. Kildare, Ireland. 
 
ABSTRACT 
 Despite the extensive use of Mumps virus vaccines for almost forty years, 
there is still a paucity of knowledge concerning the Host-Pathogen Interaction.  This 
paper reviews the advances in our knowledge of the antiviral immune response with 
particular reference to the selection of attenuated mumps virus strains used in 
different vaccine formulations.  The ability of mumps viruses to evade the interferon 
component of the immune response is described in detail.  This study also presents 
recent findings from our laboratory and others concerning the humoral and cell 
mediated responses to mumps virus.  Particular attention is placed on mumps virus 
induction of interleukin-10  (IL-10) and the potential for this to be a novel immune 
evasion strategy is discussed.  Finally, recent advances in our understanding of the 
immune response to mumps virus are placed in the broader context of our current 
understanding of this disease. 
 
INTRODUCTION: 
Mumps virus, like other members of the family Paramyxoviridae, is an 
enveloped virus with a non-segmented single stranded RNA genome of negative 
polarity. Mumps is an acute communicable disease usually characterised by fever and 
parotid swelling, although other organ systems, particularly the central nervous 
system (CNS) and glandular tissue, may be involved. Although the immune response 
to mumps virus has been explored in some detail, it is surprising how little definitive 
knowledge we possess. For example the precise roles of the antibody and cell 
mediated immune responses have not been fully elucidated [1, 2]. This review will 
place recent advances in our knowledge of the antiviral immune response in the 
broader context of our current understanding of this important childhood pathogen. 
 
HISTORY: 
The name “ mumps”  may derive from an old English verb that means “ to 
grimace, grin, or mumble” , and was the name given to an epidemic illness, first 
described by Hippocrates in the 5th century B.C. [3]. He characterised this disease by 
swelling near the ears, which was occasionally accompanied by painful swelling of 
one or both testes. In 1790, Robert Hamiliton, an English physician was the first to 
associate the involvement of the CNS with mumps, describing the neuropathology of a 
fatal case [4]. However, it wasn’ t until 1935, that Johnson and Goodpasture 
convincingly demonstrated that mumps was the result of a viral infection. They 
showed that filtered parotid secretions from a number of patients infected with 
mumps could induce parotitis in Rhesus monkeys, when injected into the Stenson 
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ducts [5]. They later went on to fulfil Koch’ s postulates, by inoculating a number of 
children with a filtrate of infected monkey parotid tissue, an experiment that would 
struggle to meet modern regulatory approval. Six out of the thirteen children 
developed noticeable parotid swelling [6]. In 1945, Habel cultured the virus in chick 
embryos, thus allowing a more practical alternative for the propagation and study of 
this infectious disease [7]. 
 
NOMENCLATURE, PHYSICAL & CHEMICAL PROPERTIES OF THE VIRUS:  
The Paramyxoviridae include important pathogens of infants and children, 
including parainfluenza viruses (PIV), mumps virus (MuV), measles virus (MV), and 
respiratory syncital virus (RSV), as well as newly discovered viruses such as Nipah 
virus [8, 9]. The family Paramyxoviridae was reclassified in 2000 into subfamilies the 
Paramyxovirinae and the Pneumovirinae. Paramyxovirinae contains three genera 
Respirovirus, Rubulavirus and Morbillivirus (Fig. 1). 
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Figure 1. Phylogenetic relationship of the Mononegavirales viruses. Mononegavirales are 
negative sense, single stranded RNA viruses, which consist of four virus families. 
 
Originally, mumps virus was classified with influenza viruses in the myxovirus 
family, but has since been reassigned to the genus Rubulavirus, based on 
nucleocapsid morphology, genome organisation, and biological properties of the 
proteins. Other members of the Rubulavirus genus include simian virus 5 (SV5), 
parainfluenza virus (PIV) types 2 and 4, and Newcastle disease virus (NDV) [10]. 
Paramyxovirus virions are pleomorphic, enveloped particles with surface 
glycoprotein spikes, projecting from this envelope. Within the envelope a large helical 
nucleocapsid encases a single-stranded, non-segmented, negative-sense RNA 
genome. The genome is complementary in its base sequence to the positive-sense 
viral mRNA that can be located in infected cells [11].  
Mumps virions range in size from 100-600nm and contain seven major 
structural proteins, whose genetic organisation has been determined, to be  
3′-NP-P-M-F-SH-HN-L-5′ [12](Table 1). The most abundant component is the 
nucleoprotein (NP), which determines the helical structure of the nucleocapsid. A 
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phosphoprotein (P) and another high molecular weight (L) protein, are also associated 
with the nucleocapsid, and may be related to the enzymatic functions of RNA 
replication [12]. A membrane, or matrix (M) protein forms the structure that underlies 
the viral envelope, and is involved in virion assembly during the replication cycle. The 
main viral envelope is composed of two glycoprotein spikes, an attachment protein, 
hemagglutinin-neuraminidase (HN) and a fusion protein (F) [10]. HN has three 
functions: it recognises sialic acid-containing receptors on cell surfaces; it promotes 
the fusion activity of the F protein, thus allowing the virus to penetrate the cell 
surface; and it acts as a neuraminidase, removing sialic acid from progeny virus 
particles to prevent self-agglutination [13]. The fusion protein is thought to be 
directly responsible for the fusion of viral envelope, with the cellular plasma 
membrane.  
The multifunctional character of the HN molecule makes it an attractive target 
for structure-based design of antiviral drugs. The structure of the HN protein of NDV 
has been reported [14]. However, these structural studies failed to reveal a second 
sialic acid binding site. Much of the literature favours two separate sites for the HA 
and the NA functions. From a drug design standpoint, a single site in HN would 
provide an attractive target for inhibiting cell attachment, fusion promotion and NA 
activities, thereby blocking both, infection by the virus and the virus spreading [14].  
The small hydrophobic (SH) protein is most likely a membrane protein 
although its functions unknown [15]. The phylogenetic relationships among mumps 
virus strains have been determined using SH gene sequences.  Interestingly this has 
revealed the SH protein as the most variable part of the mumps virus genome [16-
18], a finding which may have far reaching consequences for future subunit vaccine 
design.  
 
ANIMAL MODELS: 
The only natural host of mumps virus is man. Propagation of mumps virus 
through cell lines has increased our understanding of virus infectivity. However, 
while, in vitro experiments are a necessary part of our understanding, in vivo 
experiments allow a greater understanding of host pathogen interaction. 
Experimentally induced mumps infections have been reported in the monkey [5-6], 
however the adaptation of mumps virus to hosts other than primates has been rarely 
resulted in symptomatic disease other than when Wollenstein infected cats and 
induced parotitis, orchitis and meningitis [19-21]. Cabasso attempted to adapt mumps 
virus to guinea pigs, hamsters, mice, cotton rats, and rabbits utilising several routes, 
but all produced negative results [22]. Although the latter animals are not susceptible 
to infection, they may respond immunologically to the injection of live or killed virus. 
[22].  Infection has been reported in other species notably the dog [23], ferret [24], 
guinea pig [25], adult and suckling hamster [26, 27], mouse [28], and the developing 
chick embryo [7]. Of these animal models, the suckling hamster has attracted most 
attention. The neuroadapted Kilham strain of mumps virus produces lethal 
encephalitis in newborn hamsters [29-32]. This strain was originally isolated from 
human breast milk, and produced severe meningoencephalitis in suckling hamsters on 
intracerebral inoculation [30, 33]. Wolinsky et al. have demonstrated that the 
neuroadapted Kilham strain caused systemic infection, including the CNS in newborn 
hamsters by intraperitoneal inoculation [34].  
Using mice instead of hamsters is more beneficial, because there exists a 
greater knowledge of their genetic and immunological backgrounds. Mice have been 
central to modern understanding of T cell function (Fig. 2).  Hosaka et al. reported 
that intraperitoneal injection of an egg-adapted Urabe AM9 virus vaccine strain of 
mumps into mice generated a memory cytotoxic T lymphocyte response (CTL) [35]. 
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However, while there is a greater knowledge of the murine immune system, they have 
proved problematic for the study of this paramyxovirus.  In our studies of MuV 
immunogenicity we find no evidence of virus replication, at least in immunocompetant 
mouse strains. This absence of viral replication may limit the applicability of the 
mouse model, however it is also possible that murine studies will uncover subtle viral 
effects that could be masked by the pathology associated with replicating virus. 
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Figure 2.  Polarization of helper T cells (Th) and their cross-regulatory 
cytokines.  Antigen (Ag) encounter by dendritic cells (DC) results in T 
cell priming.  The phenotype of the response is conditioned by 
cytokines such as IL-12 present during early infection.  Mumps 
induction of IL-10 may influence this. 
 
 
 
 
PATHOGENESIS & PATHOLOGY: 
Although many animals can be readily infected experimentally, natural 
infection with mumps virus is restricted to humans. It is transmitted by droplet spread 
or direct contact [5]. The primary site of replication is located in the mucosal 
epithelium of the upper respiratory tract, which spreads to the local draining lymph 
nodes. The incubation period from exposure to first clinical symptoms is about 18 
days [36]. Secondary replication occurs in the respiratory tract, followed by 
generalised viraemia and dissemination to other organs with replication in endothelial 
cells [37]. Lymphocytic infiltration and destruction of periductal cells lead to 
blockage of the ducts in both the salivary glands and the semeniferous tubules of the 
testes, thereby inducing the classic symptoms of mumps virus infection [38]. Other 
organs may be involved in the course of mumps infection. These include the CNS, 
liver, pancreas, spleen, kidneys, heart and lungs.  
The CNS is a common target for dissemination of mumps virus, and can be 
estimated from cerebrospinal fluid (CSF) pleocytosis. In at least half of all infections, 
virus replication can be detected within the CNS [39, 40]. Most CNS involvement 
includes the meninges and the choroid plexus. Prior to the initiation of mumps 
vaccination programmes, mumps was the most common cause of childhood deafness 
and lymphocytic meningitis [38]. 
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Table 1. Physical characteristics of mumps virus components 
Viral  
Component 
Size 
(Amino acids) 
Molecular mass 
(kDa) 
Function 
    
NP 549 61-73 Determines helical 
structure of capsid. 
P 391 41-47 Enzymatic functions of 
RNA replication. 
M 375 41-42 Structural & virion 
assembly. 
F 538 65-74 Fusion of viral 
envelope. 
SH 57 - Unknown. 
HN 582 74-80 Viral entry & 
prevention of self-
agglutination. 
L 2,261 180-200 Enzymatic functions of 
RNA replication 
 
 
CLINICAL FEATURES: 
Exposure to mumps virus is followed by an asymptomatic period lasting 14 to 
18 days. Virus is present in saliva for several days before the onset of clinical 
symptoms, and for up to 5 days into the course of the disease [41]. The most 
characteristic feature of mumps virus infection is that of parotid swelling. This occurs 
in up to 95% of all symptomatic cases [42]. If swelling is severe, the mouth cannot be 
opened for pain and tightness, and is dry due to the obstruction to the flow of saliva. 
This discomfort may persist for up to a week [38]. Orchitis may occur 4-5 days after 
the onset of parotitis, or may be seen in the absence of parotid swelling.  
Lymphocytic or viral meningitis may develop about 5 days following the onset 
of clinical symptoms. Again CNS involvement can be observed following the onset of 
parotitis, but also in the absence of parotitis [43]. In the CSF, there is a marked 
increase in proteins and lymphocytes, and mumps virions can be isolated in the first 
few days. The onset of mumps meningitis is marked by, fever with vomiting, neck 
stiffness, headache and lethargy [44]. Fatality due to mumps infection stands 
between 1.6 and 3.8 per 10000 of mumps cases [45]. 
 
TREATMENT, PREVENTION & CONTROL: 
No specific antiviral chemotherapy is effective against mumps virus. A patient 
who presents with uncomplicated parotitis does not need special treatment. 
Symptomatic treatment includes simple analgesics, but for the severe pain of orchitis, 
morphia may be required. Corticosteroids are recommended in severe cases of 
parotitis, more especially in orchitis [38]. During World War II Gellis et al. carried out 
a controlled study where adult males presenting with parotitis were given either an 
intramuscular injection of 20ml of γ-globulin prepared from human convalescent 
serum or simply confined to hospital for routine non-specific symptomatic therapy 
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[46]. A partial protective effect was seen with γ-globulin obtained from convalescent 
donor serum [46]. The outcome of the study suggested that antiviral immunotherapy 
with γ -globulin was of limited utility but could be useful in selected cases early in 
the course of the disease. 
Control measures for mumps virus are primarily directed at prevention, which 
have been achieved through immunisation strategies. Various attempts to vaccinate 
against mumps have been made over the last hundred years. In one early study, 
Johnson and Goodpasture sprayed material containing parotid gland extracts bearing 
live virus into the nose and oral cavity in an attempt to immunise monkeys [47]. It 
was only in the 1960s that the first live attenuated mumps vaccine, Jeryl Lynn B, was 
developed.  It originated as an egg allantoic fluid isolate from the daughter of a 
prominent virologist [48]. And was licensed for use in the USA in 1967.  By 1992, 
this vaccine had been administered to approximately 135 million children and adults 
around the world. This resulted in the steady decline of reported mumps cases. 
However, the use of mumps vaccine remains relatively restricted to more affluent 
countries. 
There is a desirable trend in vaccine protocols to combine more components 
in fewer administrations to children. Part of this process saw the initiation of 
vaccination programmes against measles, mumps, and rubella (MMR) throughout 
Europe in the late 1980s. MMR immunisation is now part of national vaccination 
campaigns for healthy children in most parts of the world.  It is usually performed 
during the second year of life with a second dose at 4-6 years or 11-12 years, 
depending on national health policies. It has been recommend that infant immunisation 
with live attenuated measles virus should be carried out at 9 months of age [49]. 
However, Ceyhan et al. studied the efficacy of a single dose MMR delivered at 12 
months of age, compared to monovalent measles vaccination at 9 months followed by 
MMR revaccination at 15 months of age. Their results indicated a higher rate of 
vaccine failure (30.1%) after early measles vaccination followed by MMR at 15 
months of age, than MMR vaccination at 12 months of age (9.7%). It is known that 
maternal antibodies may reduce the seroconversion rates to live measles virus in 
infants under 12 months of age [50]. It is likely that the passive transfer maternal 
antibodies and the consequent interference with MMR take, is the main reason for 
primary vaccine failure [51].  Nevertheless it may be possible to devise novel 
strategies that will allow neonatal immunization [52]. 
 
STRAIN SELECTION & VACCINE DESIGN: 
As prevention of mumps infection is the only approach to controlling this 
disease it is worth outlining some of the controversies surrounding vaccine design 
and the individual attenuated strains employed. There have been five mumps vaccine 
strains in common use, detailed below.   
Jeryl Lynn mumps vaccine strain.  The Jeryl Lynn strain was developed in the USA by 
passaging isolated virus in embryonated hen’ s eggs, then in chick embryo cell 
cultures [48]. It has been reported that this isolate is in fact a mixture of two strains 
JL isolates 2 and 5 [53]. Clinical studies showed that a single dose of Jeryl Lynn 
vaccine leads to initial seroconversion rates of 80-100% [54]. Further studies show 
that the Jeryl Lynn vaccine invokes long-lived immune response.  In 1982, when mass 
vaccination began in Sweden, using the Jeryl Lynn vaccine, 73% of 229 children who 
were immunised with MMR at 18 months of age remained seropositive a decade later 
[55]. Despite the continuing mass vaccination with this strain, the less 
neuropathogenic SBL-1 strain of the mumps genotype A remains endemic in Sweden 
[56, 57]. With regard to stability of the attenuated phenotype, a 10 year retrospective 
study of hospitalised cases of mumps in the USA, found one case of aseptic meningitis 
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per 100 000 doses of MMR vaccine in a group of children aged 12-23 months [58]. 
Overall, vaccines based on the attenuated Jeryl Lynn strain have been shown to afford 
a higher seroconversion rate, with few adverse events.  
Leningrad-3 mumps vaccine strain. This vaccine strain was developed in the former 
Soviet Union in guinea-pig kidney cell culture, with further passages in Japanese quail 
embryo cultures. Vaccines using the Leningrad-3 strain have been used since 1974 in 
the former Soviet Union and other countries. Studies have shown that children aged 
1-7 years have a seroconversion rate of 89-98%, and a protective efficacy of 92-
99% [59]. Further retrospective review of the medical records of Slovenian patients 
hospitalised with aseptic meningitis during 1979-1986 found a high incidence of 1 
case per 1000 doses of a combined measles, mumps (Leningrad-3) vaccine, however 
all symptoms are reported to have resolved with no further complications [60]. 
Nevertheless this incidence prompted the search for improved attenuated strains. 
Leningrad-Zagreb mumps vaccine strain. This vaccine was developed in Croatia, by 
further attenuation of the Leningrad-3 strain by adaptation and passage on chick 
embryo fibroblast cell culture. Studies in Croatia showed 87-100% seroconversion to 
L-Zagreb mumps vaccine and efficacy of 97-100% [61]. In 1993, Tesovic et al. 
reported an equally high incidence of 1 case of aseptic meningitis for each 1000 
doses of MMR (L-Zagreb strain), among children vaccinated at a median age of 14 
months [62]. In Brazil, da Cunha et al. examined the occurrence of aseptic meningitis 
and mumps as an adverse event of L-Zagreb-MMR vaccine. They showed a marked 
increase in the number of notified cases of aseptic meningitis, 3-4 weeks after mass 
immunisation with L-Zagreb-MMR [63]. 
Considering that Leningrad-Zagreb vaccine strain was developed by further 
passage of Lenigrad-3 virus vaccine strain, the high incidence of aseptic meningitis 
may not be surprising. Clearly, a 0.1% chance of CNS involvement associated with a 
vaccine is not desirable, and is one reason for the limited application of these vaccine 
formulations.  
Rubini mumps vaccine strain. This vaccine was isolated from the urine of a child by 
isolation in the human diploid cell W138 that was subsequently passaged through 
embryonated hen’ s eggs, and adapted to the MRC-5 human diploid cell line [64]. 
The Rubini vaccine was licensed in Switzerland in 1985. Recent studies in 
Switzerland, Italy and Portugal provide evidence that mumps vaccine based on the 
Rubini strain does not appear to offer long-term protection against mumps infection 
[65]. Several studies have confirmed the low efficacy of the Rubini vaccine virus 
strain [66, 67]. A study of secondary attack rates among family contacts of confirmed 
mumps cases found a protective efficacy of just 6% for the Rubini vaccine, compared 
with 73% for the Urabe vaccine and 62% for the Jeryl Lynn vaccine [66]. The poor 
efficacy of this strain is borne out by the experience in Portugal. In 1992, this country 
began to immunise with the Rubini MMR vaccine strain exclusively. However, this was 
followed by a mumps epidemic in 1995-96, with the highest incidence among children 
aged 1-4 years. This epidemic appeared to be correlated to the introduction of the 
Rubini vaccine virus strain [68]. In a study carried out in Germany, Tischer et al. 
looked at the humoral immune response when children were immunised with three 
different MMR vaccines. They showed that immunisation with MMR containing the 
Rubini component induced detectable antibody in only 38% of the vaccines [69]. 
Whether low antibody titres can protect against disease is unknown, but the fact that 
only 38% of vaccinees presented detectable antibody, either the initial responses 
were poor, or that this Rubini strain does not induce lasting memory responses.  
Urabe mumps vaccine strain. Urabe AM9 vaccine was produced from a 1967 Japanese 
isolate, by six passages in chick amniotic cavity followed by two plaque-to-plaque 
purifications in monolayers of quail embryo fibroblasts [70]. Urabe AM9 mumps 
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vaccine virus, was combined with measles and rubella vaccine virus into the MMR 
formulation, and was introduced into Canada and the UK. In Canada, one study found 
that 5-6 years after one dose of MMR the seropositivity rate was 93%, compared with 
85% for the Jeryl Lynn vaccine strain [71]. In the UK, a similar study showed that 4 
years after a single dose of MMR vaccine, that seropositivity rates were 85% 
compared with 81% for the Jeryl Lynn vaccine strain. However, following reports 
from physicians of aseptic meningitis post vaccination, Canada initiated a series of 
studies.  These showed that the Urabe vaccine strain was also a mixture of viruses 
[72]. In 1990, Canadian authorities withdrew the license to distribute the MMR 
vaccine containing the Urabe AM9 mumps vaccine strain, because the casual 
association of vaccination with the occurrence of aseptic meningitis was established 
unequivocally [73, 74]. Parallel studies in the United Kingdom have examined aseptic 
meningitis rates following immunisation with the Urabe virus vaccine strain. One 
multi-centre study showed a rate of 9 aseptic meningitis cases per 100 000 vaccine 
doses[75]. These and other studies led to suspension of vaccine distribution in the 
UK in 1992. Likewise, Japan undertook a nationwide surveillance in 1989, 
demonstrating an overall rate of 49 cases of aseptic meningitis per 100 000 doses of 
vaccine [76]. The distribution of the domestically produced MMR vaccine containing 
the Urabe mumps strain was suspended from use in 1994. 
 Despite these drawbacks it must be appreciated that well over 100 million 
doses of mumps-virus containing vaccines have been delivered in the U.S., with few 
adverse reactions [77]. Those events that are reported are rash, pruritus and 
purpura, which tend to be allergic in nature and frequently, resolve themselves. A 
survey of the literature by the Vaccine Safety Committee of the Institute of Medicine 
failed to find any relationship between the administration of mumps virus containing 
vaccines and the development of encephalopathy, encephalitis, Guillain-Barre 
Syndrome, or Type I insulin-dependent diabetes mellitus [78].  Considering the scale 
of the mass vaccination programme this is a powerful indication of the safety and 
beneficial nature of the mumps component of these vaccines. 
Recently, it has been postulated that MMR vaccination might be linked with a 
reported increase in autism in some countries or with atypical bowel diseases [79]. 
This has prompted a great deal of scientific examination and also public anxiety in 
some countries.  The results of this extensive examination failed to find any evidence 
to support either claim [80-84]. The result of the initial claims has been a decline in 
vaccine coverage in some countries with the result that many children are now at risk 
of measles, mumps and rubella, and that the possibility of eradication of measles has 
been delayed. 
 
 HOST-PATHOGEN INTERACTION: 
Improved vaccine formulations will only come from an enhanced understanding 
of both the host and the virus.  Given the short generation times of paramyxoviruses, 
a rapid host response is essential and must be aimed at several different levels. The 
portal of entry for mumps virus is the airway mucosa so clearly the virus has 
developed strategies to overcome the mechanical protection afforded by muco-ciliary 
clearance.   Natural killer (NK) cells are known to be significant effector components 
of the innate immune system, which aid in the initial defence against viral infection 
both via direct cellular cytotoxicity and by the production of inflammatory cytokines. 
In mice, NK cell-mediated cytotoxicity and IFN-g production occur early in the 
course of infection by RSV, and the presence of NK cells is associated with the 
subsequent influx of CD8+ T cells [85]. Nevertheless, NK cells seem to afford only 
limited early defence against mumps virus, Clearly an important early immune system 
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task is to containing infection prior to the development of adaptive immunity and 
prevent overwhelming infection.  This function is usually ascribed to interferon (IFN). 
  Interferons are a family of cytokines that were discovered as soluble factors 
that mediate cellular resistance to virus infection. They can be classified into two 
groups; type I and II. Type I IFNs, may be produced by any cell in response to viral 
infection, whereas type II IFN, is produced in response to the recognition of infected 
cells by activated T and NK cells. The antiviral functions of IFN are mediated by 
induction of IFN-stimulated genes (ISGs) such as 2´, 5´-oligoadenylate synthase (2-
5AS), and dsRNA activated protein kinase (PKR) [86]. Fujii et al. reported that 
various cell lines, which were persistently infected with mumps virus, exhibited a 
poor induction of 2-5AS and PKR [87, 88]. However, not only have paramyxoviruses 
been shown to disrupt the interferon signalling pathway, Sendai virus (SeV) infection 
also renders both human and murine cells unresponsive to IFN-α /β  [89]. STAT 
proteins are activated by the JAKs after stimulation with appropriate cytokines. Mice 
deficient in STAT1 and STAT2 proteins correlate with inactivation of the IFN 
pathway [90, 91]. A decrease in STAT-1α , rather than the down-regulation of IFN-
receptors, IRF-1and IRF-2, causes the suppression of these IFN-induced genes [92]. 
The anti-IFN strategies employed by viruses to circumvent the interferon 
response include, (1) inhibition of functions of IFN-induced antiviral proteins, (2) 
suppression of interferon production and (3) interference with IFN signal transduction 
[93-95].  It is not surprising given the pathogenic nature of mumps virus that it too 
has evolved strategies to counter the effect of IFNs.  
Most paramyxoviruses encode the P, V, and C proteins from the same gene by 
using alternative initiation codons and mRNA editing mechanisms [96]. The P protein 
is a structural component of the viral RNA polymerase, whereas V and C proteins are 
virus-encoded accessory factors whose function in some paramyxoviruses is 
inhibition of the IFNα/β signalling pathway. Studies on the V protein of SV5 (simian 
virus 5) by Didcock et al. showed that the STAT1 level decline from around 4 hours 
after infection and eventually become undetectable [97]. The ability of the SV5 V 
protein to degrade STAT1 and block IFN signalling was confirmed by Andrejeva et 
al., using 2fTGH cells constitutively expressing SV5 V protein. These results 
demonstrated that the SV5 V protein blocks IFN signalling by targeting STAT1 for 
proteaosome mediated degradation [98]. The cysteine-rich V protein of mumps virus 
inhibits the JAK/STAT pathway by inducing the degradation of STAT1 [92, 99, 100]. 
(Fig. 3). 
It is interesting to note that STAT1 is targeted by most of the rubulaviruses. 
STAT1 is not only a critical component of the IFN signalling pathway, but also serves 
as a molecule involved in the constitutive expression of certain genes including 
caspases [101, 102], and low molecular polypeptide 2 (LMP2) [103]. LMP2 is a 
subunit of the proteasome involved in the processing of T-cell antigens. MHC class-I 
antigen is necessary for the presentation of endogenous virus antigens on cell surface 
membranes. It is well known that the IFN-g signalling pathway through induction or 
activation of the ISGF-3 complex regulates MHC class-I expression. Thus, 
inactivation of STAT-1α  could be correlated with a decrease in MHC class-I 
expression. This decrease allows cells persistently infected with mumps virus to 
escape host immunosurveillance [99]. 
 105
M. Flynn & B.P. Mahon               Chapter 6: Immune Response to Mumps Viruses 
Recent Research Developments in Virology, 5 (2003):97-115  ISBN:81-7895-094-4  
MuV 
b
IFN
a g
JAK JAK 
STAT2
Nuclear  
membrane
STAT2 STAT1 
STAT1 v+
STAT1 degraded
ISGF3 STAT2 STAT1 STAT1 STAT1
ISGs ISGs
Surface  
membrane
ISRE GAS
Figure 3.  Disruption of Interferon(IFN)  signalling pathways.  Paramyxoviruses inhibit 
signalling by degrading STAT-1.  The cysteine rich V protein of Mumps is a candidate for 
this function.ISRE=Interferon secreting response element, GAS = Interferon gamma 
activated site, ISG=Interferon secretion genes. 
 
ANTIBODY RESPONSES TO MUMPS VIRUS: 
Protection against virus infection is determined by cell-mediated and humoral 
immune responses. Humoral immunity is mediated by antibody. The simplest and most 
direct way in which antibodies can protect from pathogens is by binding and blocking 
access to permissive target cells (neutralisation). However antibody may work in a 
wide variety of ways that includes opsonization, activation of complement, countering 
viremia, and through mediating antibody-dependent cell-mediated cytotoxicity. 
The role of the specific humoral response, to mumps virus, as a defence factor 
has not been definitively explained [1]. Several authors have shown that mumps virus 
elicits the production of specific antibodies IgM and IgG [104, 105]. High serum 
levels of the specific antibodies IgM and IgG are evidence of the exposure of the 
immune system to viral antigens. During the course of immunisation with MMR, the 
primary immune response to mumps is marked by the increase in specific IgM 
antibodies. While administration of a second dose of MMR vaccine elicits a large 
boost in IgG antibody levels, with little or no IgM response: the so-called anamnestic 
or secondary response [106]. 
It might be expected that the early invasion of the salivary glands and other 
organs, should induce sufficient specific antibody to prevent the spread of the virus, 
and counter potential meningitis, the most frequent serious complication in the natural 
course of infection. However, Johnstone et al. provided evidence to the contrary 
[107]. Comparing patients with mumps meningitis with or without parotid 
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involvement, high titres of antibodies directed against internal ribonucleoprotein core 
soluble antigen than high titres of antibodies directed against envelope antigen [107]. 
Attempts to dissect the role of antibody have been hampered by the 
difficulties surrounding the animal models described above. For example in our early 
studies, murine immunisation by intra muscular and intra peritoneal, using alum as an 
adjuvant, or by the intra nasal route with doses as high as 1/10 human dose failed to 
induce serum or mucosal antibody responses. Even when purified mumps virus was 
delivered in complete Freunds adjuvant by the intra muscular route little or no 
specific IgG could be detected, although CD4+ T cell responses were induced (see 
below).  
The measurement of immune responses to mumps virus remains a 
controversial issue. Determination of mumps virus specific antibodies in human sera 
is hampered by false positive results, due to the fact that, there is considerable 
cross-reactivity between mumps virus and other paramyxoviruses [108].  
Nevertheless, a variety of assays for antibodies can be applied successfully to sera to 
demonstrate whether an individual has either been exposed to infection or responded 
to vaccination. However, quantitative assays are required, if the levels of immunity 
are to be estimated, and for mumps these remain problematic [109]. Pipkin et al. 
described assays based on plaque reduction, microtitre plate neutralization, 
haemagglutination inhibition, and ELISA. They reported that the antibody titres 
measured by HI or ELISA was poorly predictive of each other or of the neutralising 
antibody titrer. ELISA titers were markedly higher than in neutralising titer as might 
be expected, and some individuals seroconverted by ELISA but not by neutralisation 
[109]. Christenson and Bottiger reported similar results [110]. The serum antibody 
titer in response to vaccination is typically lower than that observed in children 
naturally infected with mumps [111]. If antibody is the protective mechanism then 
there is a possibility that vaccinees may become infected at a later date. However, 
the difficulty in obtaining accurate results from humans, who are the natural hosts of 
mumps virus, doesn’ t bode well for researchers investigating mumps virus 
immunogenicity in non-permissive hosts. 
It has been reported that secretory antibody is produced in saliva after natural 
mumps infection, and that most of the neutralising antibody is of the IgA class [112, 
113]. Since local secretory neutralising antibodies act directly, Tanaka et al. have 
gone on to show that nasal antibody is important in protecting the host against mumps 
infection [114]. They showed that secretory IgA (sIgA) with neutralising activity was 
produced in the nasal cavity after vaccination as well as after natural mumps 
infection. Presence of nasopharyngeal antibody suggests that the memory of the local 
immune system in the nasal cavity, which is the initial site for the invasion and 
replication of mumps virus, was well maintained. Cusi et al. discovered that intranasal 
immunisation with mumps virus DNA vaccine delivered by influenza virosomes into 
mice, elicits mucosal and systemic immunity [115]. IgA antibodies were detected in 
faeces of mice 7-10 days after the last immunisation, which indicated that intranasal 
immunisation of DNA induces mucosal immunity at the enteric site [115]. 
Studies with murine monoclonal antibodies suggest that the hemagglutinin-
neuraminidase protein (HN) is the major target for the humoral response to mumps 
virus infection [116]. Cusi et al. localised a neutralising epitope on the mumps virus 
heamagglutinin-neuraminidase protein [117]. Their aim was to characterise further 
putative neutralising epitopes by using sera of mice previously immunised with 
fragments of HN protein and to confirm and localise those putative epitopes on the 
HN protein by using synthetic peptides [117]. They discovered that a fragment of the 
HN protein spanning aa 329-335 could, not only be relevant for the virulence of 
mumps virus but also for the induction of neutralising antibodies. This fragment was 
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shown to have the ability to induce neutralising antibodies not only to the attenuated 
virus strain, but also a wild-type strain. The presence of antibodies to the HN of 
mumps virus in the mucosa is important, since they represent barrier immunity [115]. 
Thus the HN protein represents the major target to induce a protective humoral 
response to mumps virus [118]. 
 
CELL-MEDIATED RESPONSES TO MUMPS VIRUS: 
Ziola et al. demonstrated that T-cell cross-reactivity occurs among members 
of the three genera comprising the Paramyxoviridae. He demonstrated that the 
Paramyxoviridae cross-react at the T-cell level, but not at the antibody level [119]. 
T-cell reactivity between mumps virus and parainfluenza virus, is expected as these 
viruses are serologically related [120]. However, Ziola et al. uncovered a strong bi-
directional T-cell cross-reactivity between respiratory syncytial virus (RSV), 
measles virus and mumps virus [119]. RSV typically infects children before one year 
of age [121], and thus many children will have acquired T-cell immunity before they 
reach the recommended age for MMR vaccination (12-15 mths). This means that 
RSV-induced T-cells, through cross reactivity with mumps and measles virus 
antigens, could influence subsequent development of immunity to either or both of 
these vaccine viruses [119]. 
On entering the target cell, mumps virus is not accessible to antibodies. 
Therefore cell mediated immunity mediated by CD4+ T helper (TH) or CD8+ cytotoxic 
T cells (CTL) are essential in the elimination of viruses [122].  Cell mediated 
reactions depend on direct interactions between specific T cells and target or antigen 
presenting cells which display the specific antigen in the context of either class I or II 
MHC molecules. However, it is known that rubulaviruses target STAT1 for 
degradation (Fig 3.), which may be correlated to a decrease in MHC class-I 
expression [99]. The decrease results in reduced CTL activation, thus favouring 
mumps virus replication and dissemination.  
The role of cellular immunity in infection with mumps virus is supported by 
data derived from experimental animals [2], as well as from humans. Mumps 
meningitis is a common complication of mumps virus infections, and MuV-specific 
CTL accumulated in the CNS can be detected in cerebrospinal fluid (CSF) [123]. 
Nagai et al. demonstrated that at the acute phase of mumps meningitis, CD8+ and 
HLA-DR+ cells increased in the CSF, and that cytotoxic-suppressor T cells activated 
by MuV antigens may accumulate [124]. Kimura et al. were the first to focus on the 
T-cell receptor (TCR) gene repertoire in patients with infectious CNS diseases. They 
evaluated TCR Vα  gene expression in T lymphocytes from patients with mumps 
meningitis, and showed that the use in the CSF was widespread but biased toward 
three or less families in each patient. The biased use of the Vα  gene suggests that T 
cells with dominant Vα  genes may be mumps-specific T lymphocytes, which were 
selectively recruited to the CNS [125]. 
A major goal of vaccine development has been to design viral vectors that 
elicit CTL that can efficiently clear an ongoing or subsequent infection. Parks et al. 
showed that recombinant Simian virus-5 (rSV5) expressing chicken ovalbumin, was 
capable of eliciting a robust CTL response [126]. More importantly, vaccination with 
rSV5-Ova was found to efficiently elicit high avidity CTL. This is an extremely 
desirable attribute of a vaccine vector, as high avidity CTL have been shown to be 
optimal for virus clearance [127].  
Investigations by Cusi et al. demonstrated that immunisation with a mumps 
virus DNA vaccine delivered by virosomes elicited not only mucosal immunity but 
systemic cell-mediated immunity too [115]. They carried out proliferation assays, 
which predominantly measure CD4+ T-cell responses. Cells from mice immunised 
 108
M. Flynn & B.P. Mahon               Chapter 6: Immune Response to Mumps Viruses 
Recent Research Developments in Virology, 5 (2003):97-115  ISBN:81-7895-094-4  
with live mumps induced mainly IL-10 and, to a lesser extent, IL-2. IFN-g was not 
seen in any of their samples, which may be explained by the fact that mumps virus 
holds the ability to suppress the IFN system [100]. When Cusi et al. immunised via 
the mucosal route with mumps virus HN-virosomes a Th2 response was observed, 
while immunisation with mumps virus F-virosomes characterised a Th1 response. A 
combination of these two vaccines containing both mumps virus HN and F proteins 
could be necessary for a vaccine capable of inducing cellular and humoral immunity 
[115]. 
 Our own studies of murine immunisation with MMR could only elicit responses 
when powerful adjuvants were employed.  However, mumps virus specific polyclonal 
T cells lines could be derived from these mice (Fig. 4A). Analysis of these lines 
demonstrated MuV-specific proliferation and cytokine release. Interestingly IL-4, IL-
5 and IFN-g were not detectable. However significant levels of IL-10 were elicited in 
response to mumps virus stimulation. Thus even following a powerful immunisation 
regimen, mumps virus is only sparingly immunogenic, and seems to favour IL-10 
induction. Cusi et al. also discovered that when purified live mumps virus was 
inoculated into BALB/c mice IL-10 was the principal cytokine induced [115]. To 
probe these responses further and to understand the mechanism of viral modulation 
within the murine model, it will be necessary to derive mono-specific T cell clones. 
In preliminary studies, we have derived a panel of MuV-specific CD4+ T cell 
clones. Results of two representative clones are shown (Fig. 4A). Clone MuV1.1 
proliferates and secretes high levels of IFN-g, with little or no IL-4, IL-5 or IL-10 
produced. High levels of IFN-γ  drive the characteristic TH1 response needed to 
destroy intracellular parasites. Secretion of IFN-g by MuV1.1 does not appear to be 
consistent with previous studies [115]. However, individual proteins of mumps virus 
may have the ability to elicit opposing T cell responses. Cusi et al. demonstrated that 
the F protein when entrapped in influenza virosomes secreted increased amounts of 
IgG2a and IL-2, suggestive of a Th1 response, yet they observed no IFN-g secretion 
[115]. Taken together these results suggest that at least under some conditions, 
mumps virus immunisation can induce IFN-g In contrast to MuV1.1, a second clone, 
MuV3.1 proliferated and secreted IL-5 and high levels of IL-10, but little or no IFN-g 
in response to mumps virus (Fig4B). This is consistent with the response observed by 
Cusi et al. They showed that when HN was entrapped in influenza it stimulated a TH2 
response, production of IgG1 and IL-10 [115]. Further characterisation of both MuV-
specific T cell clones by FACS analysis confirmed that they are CD3+CD4+CD8- T 
cells (Fig 5).  
Interestingly, both Cusi et al and our studies showed high levels of IL-10. This 
may be a feature of the mouse, which is not permissive to MuV replication. However, 
it may be that different MuV antigens provoke different cytokine profiles [115]. Cusi 
et al. suggested that IL-10 was indicative of a TH2 response. However, recent work 
on IL-10 suggests that it is modulatory, acting as a regulatory or suppressor function 
during an immune response. It is known that Paramyxoviruses overcome the antiviral 
properties of IFNs, while other viruses have evolved immunosuppressive strategies 
by encoding homologues of immunomodulatory cytokines, including IL-10.  It may be 
that induction of host IL-10 by mumps virus is an additional mechanism to evade host 
immunity.  A number of intriguing possibilities arise from the data described above.  It 
is clear that attenuated mumps virus delivered alone or as MMR can generate TH1 and 
TH2 specific profiles. The observation of high levels of IL-10 seen by Cusi and also 
presented here suggests a viral evasion strategy in which mumps induces IL-10 in 
order to suppress protective cell mediated responses [115]. However, an alternative 
hypothesis may be worthy of investigation.  Mumps viremia is associated with fever 
presumably due to endogenous cytokines such as IL-1.  The induction of IL-10 by 
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mumps may in fact be a protective mechanism, by dampening the immune response. 
The virus may counter the potentially pathological influence of inflammation. Mumps 
like other viruses requires time to replicate and disseminate from the host to others.  
It is counter productive for the virus to allow overwhelming inflammation, which 
would compromise the host and its own spread. IL-10 may be beneficial to both virus 
and the survival of the host.  While the latter possibility is startling it will require 
animal models and particularly gene knockout models to determine which of these 
roles IL-10 promotes. The viral components that generate the suppressive 
environment will also need to be identified and removed from future subunit vaccines 
as they may suppress active immune responses to viral antigens of mumps virus and 
perhaps other components. 
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Figure 4. Murine CD4+ Th response to MuV immunization.  A) Two Mumps virus specific T
cell lines were established after a single round of in vitro restimulation.  Proliferation and IL-
10 secretion are shown in response to control (open bar), MuV (hatched bar) or Mitogen
positive control (Black bar). B) Characterization of Two T cell clones MuV1.1 and MuV 3.1 in
response to control, virus or mitogen stimulation, with regard to Proliferation, or IL-5, IL-10
or IFN-g secretion 
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B: MuV3.1 
A: MuV1.1 
Figure 5. Characterization of MuV specific clones by FACS analysis as CD4+ T 
cells. A Clone MuV1.1 is a Th1 type clone whereas (B) Clone MuV3.1 has a Tr 1 
phenotype. 
Conclusions: 
Safe and effective combination vaccines, containing live attenuated mumps virus 
strains, have been in use around the world since the early 1980s. However, while 
mumps has been documented since the 5th century B.C. there is still little 
understanding of the complexity of the immune response it generates. The mouse has 
opened the gateway to our understanding of the human immune system and how it 
responds to invading pathogens. Examination of mumps virus is hitherto been 
hampered by the fact that viral replication is restricted to humans and select 
primates[6, 128]. However, the mouse and mumps-specific T cell clones may prove 
more beneficial in uncovering viral mechanisms of immune evasion. The time is right 
for a renewed interest in the fundamental biology of mumps virus and how it interacts 
with permissive and non-permissive hosts. Such fundamental knowledge will be 
essential if we are to design new vaccines by rational criteria. 
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